DBVT Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

DBV Technologies SA has a consensus price target of $21.81, signalling upside risk potential of 347.91%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 852.19%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than DBV Technologies SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of 0.707, which suggesting that the stock is 29.271% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. DBV Technologies SA's net income of -$30.4M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 1.71x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of -142.32%. DBV Technologies SA's return on equity of -- beat Cellectis SA's return on equity of -79.78%.

DBV Technologies SA has a consensus price target of $21.81, signalling upside risk potential of 347.91%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 367.74%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of 0.707, which suggesting that the stock is 29.271% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.275, suggesting its more volatile than the S&P 500 by 227.454%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $16.2M. DBV Technologies SA's net income of -$30.4M is lower than Cellectis SA's net income of -$23.1M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 3.82x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -48.85%. DBV Technologies SA's return on equity of -- beat Edap TMS SA's return on equity of -42.5%.

DBV Technologies SA has a consensus price target of $21.81, signalling upside risk potential of 347.91%. On the other hand Edap TMS SA has an analysts' consensus of $10.67 which suggests that it could grow by 369.9%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of 0.707, which suggesting that the stock is 29.271% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.782%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.4M. DBV Technologies SA's net income of -$30.4M is lower than Edap TMS SA's net income of -$7M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 1.23x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Genfit SA's return on equity of --.

DBV Technologies SA has a consensus price target of $21.81, signalling upside risk potential of 347.91%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 200.01%. Given that DBV Technologies SA has higher upside potential than Genfit SA, analysts believe DBV Technologies SA is more attractive than Genfit SA.

DBV Technologies SA has a beta of 0.707, which suggesting that the stock is 29.271% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.542%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. DBV Technologies SA's net income of -$30.4M is higher than Genfit SA's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 2.54x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.